Your browser doesn't support javascript.
loading
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.
Brana, I; Berger, R; Golan, T; Haluska, P; Edenfield, J; Fiorica, J; Stephenson, J; Martin, L P; Westin, S; Hanjani, P; Jones, M B; Almhanna, K; Wenham, R M; Sullivan, D M; Dalton, W S; Gunchenko, A; Cheng, J D; Siu, L L; Gray, J E.
Afiliación
  • Brana I; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Berger R; Sheba Medical Center, Ramat Gan, Israel.
  • Golan T; Sheba Medical Center, Ramat Gan, Israel.
  • Haluska P; Mayo Clinic, Rochester, MN, USA.
  • Edenfield J; Greenville Health System - Cancer Institute, Greenville, SC, USA.
  • Fiorica J; Sarasota Memorial Hospital, Sarasota, FL, USA.
  • Stephenson J; Greenville Health System - Cancer Institute, Greenville, SC, USA.
  • Martin LP; Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Westin S; University of Texas - MD Anderson Cancer Center, Houston, TX, USA.
  • Hanjani P; Abington Memorial Hospital, Abington, PA, USA.
  • Jones MB; Merck & Co., Inc., North Wales, PA, USA.
  • Almhanna K; H Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Wenham RM; H Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Sullivan DM; 1] H Lee Moffitt Cancer Center, Tampa, FL, USA [2] M2Gen Tampa, Tampa, FL, USA.
  • Dalton WS; M2Gen Tampa, Tampa, FL, USA.
  • Gunchenko A; Merck & Co., Inc., North Wales, PA, USA.
  • Cheng JD; Merck & Co., Inc., North Wales, PA, USA.
  • Siu LL; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Gray JE; H Lee Moffitt Cancer Center, Tampa, FL, USA.
Br J Cancer ; 111(10): 1932-44, 2014 Nov 11.
Article en En | MEDLINE | ID: mdl-25290091
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Propionatos / Sulfonas / Derivados del Benceno / Sirolimus / Compuestos Heterocíclicos con 3 Anillos / Anticuerpos Monoclonales / Neoplasias Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Propionatos / Sulfonas / Derivados del Benceno / Sirolimus / Compuestos Heterocíclicos con 3 Anillos / Anticuerpos Monoclonales / Neoplasias Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Canadá